Netherlands
About argenx SE
argenx SE is a commercial-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. Operating globally, including in the United States, Japan, China, and the Netherlands, the company is dedicated to advancing treatments for patients with severe autoimmune conditions.
Key Products & Therapies
- VYGART & VYGART HYTRULO – Treatments for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
- Efgartigimod – Investigational therapy for seronegative/ocular gMG, thyroid eye disease, ITP, myositis, Sjögren’s disease, lupus nephropathy, and other autoimmune disorders.
- Empasiprubart – Targets multifocal motor neuropathy, CIDP, delayed graft function, and dermatomyositis.
- ARGX-119 – A MuSK agonist for congenital myasthenic syndromes, amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy.
Pipeline & Research
argenx is advancing a diverse pipeline of experimental therapies, including:
- ARGX-109 – Targets IL-6 to reduce inflammation.
- ARGX-121 & ARGX-220 – Immune system modulators.
- ARGX-213 – Focused on FcRn inhibition.
- ARGX-118 – Antibodies against Galectin-10.
- Additional candidates: cusatuzumab, ARGX-112, ARGX-114, ARGX-115.
Strategic Collaborations
The company partners with leading institutions and biopharma firms, including:
- OncoVerity, Inc.
- LEO Pharma A/S
- Zai Lab Limited
- AbbVie, Inc.
- Genmab SE
- Chugai Pharmaceutical Co., Ltd.
Founded: 2008 | Headquarters: Amsterdam, the Netherlands
